← boardnext 2027-11next 2028-08next 2043-07
AUTL
Autolus Limiteddistress 8/10 · high distress / dilution risk$1.42-1%today-47% from 52w high
Lead: lupus nephritis · est. market ~$5B (approx, global)
Revenue
$26M
Liquidity
$131M
Runway
0.5 yrs
Shares 1y
0%
Price & events
-6.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-2.8%
1W
-14.5%
1M
-7.2%
3M
-2.8%
6M
-47.0%
1Y
-66.9%
2Y
-74.3%
5Y
-84.8%
All
Overview
- Market Cap
- $377.78M
- Volume
- 52.13K
- 52 Week Range
- $1.21 – $2.68
- Total Shares
- 266.16M
- Float Shares
- 33.90M
- Short %
- 7.24%
- % Held by Insiders
- 18.08%
- % Held by Institutions
- 64.66%
- RVOL
- 0.05x
Pipeline stages · 3 programs
AUTO1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Obecabtagene autoleucel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AUTO CAR T cell therapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-11 Estimated 50% readout ~2027-12-01 | Phase 1 | AUTO1 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 2 | Obecabtagene autoleucel | Lupus Nephritis | — | recruiting |
| 2029-06-30 Estimated 50% readout ~2029-08-14 | Phase 1/2 | AUTO1 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | — | active not recruiting |
| 2043-07 Estimated 50% readout ~2043-08-15 | Phase 2 | AUTO CAR T cell therapy | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma | — | enrolling by invitation |
Catalyst news & presentations · 14
- 2028Guided 40%readoutPhase 2obe-cel · Data readout for LUMINA Phase 2 trialSEC 8-K
- end of 2027Guided 40%readoutPhase 2obe-cel · Data readout for CATULUS Phase 2 trialSEC 8-K
- year-end 2026Guided 40%readoutPhase 1obecabtagene autoleucel (AUCATZYL) · Initial clinical data from BOBCAT Phase 1 trialSEC 8-K
- end of 2026Guided 40%readoutPhase 1obe-cel · Initial data readout for BOBCAT Phase 1 trialSEC 8-K
- 2026-08-07Estimated 45%earningsEarningsEarnings releaseyahoo
- 2H 2025regulatory submissionFiled (NDA/BLA)obecabtagene autoleucel · EU/UK approvals expected.SEC 8-K
- H2 2025readoutobe-cel · Notification from UK and EU regarding approval in ALLSEC 8-K
- H2 2025regulatory submissionFiled (NDA/BLA)obe-cel · MHRA and EMA marketing authorizations expectedSEC 8-K
- by year-end 2025trial initiationsecondaryPhase 1obecabtagene autoleucel · Dose first patient in Phase 1 dose escalation studySEC 8-K
- second half of 2025conferencedata presentationsecondaryPhase 1obecabtagene autoleucel · Full data from Phase 1 CARLYSLE trial at medical conferenceSEC 8-K
- by year-end 2025trial initiationsecondaryPhase 1obe-cel · dose first patient in Phase 1 trialSEC 8-K
- Mid-Year 2025readoutPhase 2obecabtagene autoleucel · Longer-term follow-up data from FELIX trialSEC 8-K
- 23 AprilreadoutPhase 1obe-cel · Initial data from PY01 trial of obe-cel in pediatric ALLSEC 8-K
- 2025-01-13conferencedata presentationsecondaryCorporate update at J.P. Morgan Health Conference.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+502% upside) · 8 analysts
- 2026-05-14HC Wainwright & Co.Buy
- 2026-04-09NeedhamBuy
- 2026-03-31MizuhoOutperform
- 2026-03-27NeedhamBuy
- 2026-02-17HC Wainwright & Co.Buy
- 2026-01-12NeedhamBuy
Competitors — lupus nephritis
- NVSEFNOVARTIS AG$292.0B · D3
- AUPHAurinia Pharmaceuticals Inc.$1.9B · D0
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- KYTXKyverna Therapeutics, Inc.$439M · D5
- LYELLyell Immunopharma, Inc.$294M · D5
- FATEFATE THERAPEUTICS INC$294M · D3
- NKTXNkarta, Inc.$166M · D3
- ACETAdicet Bio, Inc.$78M · D5
- ATRAAtara Biotherapeutics, Inc.$71M · D7
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Autolus Therapeutics: Navigating A Bumpy 2026 (NASDAQ:AUTL) - Seeking Alpha
- 2026-07-14Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees - Yahoo Finance
- 2026-07-05AUTL PE Ratio & Valuation, Is AUTL Overvalued - Intellectia AI
- 2026-07-01Director at Autolus (AUTL) granted stock options and RSUs as compensation - Stock Titan
- 2026-07-01Autolus Therapeutics (AUTL) director granted options and RSUs tied to ADSs - Stock Titan
- 2026-07-01Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs - Stock Titan
- 2026-07-01Autolus (NASDAQ: AUTL) director awarded 47,500 options and 31,667 RSUs - Stock Titan
- 2026-07-01Autolus Therapeutics (AUTL) director receives new option and RSU equity awards - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.